BioWorld

Feb. 8, 2005

View Archived Issues

Pivotal Phenserine Data Drop Axonyx's Stock By 62 Percent

Axonyx Inc. lost almost two-thirds of its value on Monday with news that its lead Alzheimer's disease product, Phenserine, failed in a European Phase III trial. (BioWorld Today) Read More

Specialty Pharma Partnering Can Bring Focus, Expertise

Read More

Takeda Paying $270M Cash For Syrrx Presence In States

Read More

Intarcia IPO Seeks $86.25M For Cancer, HCV Therapies

Read More

Vicuron Reports Positive Phase III Results, Plans Third-Quarter NDA

Read More

Other News To Note

Read More

Appointments And Advancements

Read More